The bioavailability of sustained release nicotinic acid formulations.

1. The bioavailability of three nicotinic acid formulations was investigated in a randomized cross-over study. 2. Single doses of nicotinic acid (500 mg) were given to seven healthy volunteers. The concentrations of nicotinic acid and its main metabolite nicotinuric acid were measured in serum up to 8 h and in urine up to 24 h. 3. The relative bioavailability of unchanged nicotinic acid from two slow release formulations compared with a rapid-release form was only 1% and 25%, respectively. Relative values of AUC (0.8 h) for nicotinuric acid were 15% and 58%, and relative urinary recoveries were 18% and 59%, respectively. Facial flushing was less when slow release formulations were used. 4. The bioavailability of unchanged nicotinic acid is low and the ratio of nicotinuric acid to nicotinic acid in serum and urine is high when slow release formulations are used.

[1]  K. Johnson,et al.  Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin. , 1990, JAMA.

[2]  H. Hodis.  Acute hepatic failure associated with the use of low-dose sustained-release niacin. , 1990, JAMA.

[3]  L. Benet,et al.  Pharmacokinetics of nicotinic acid – salicylic acid interaction , 1989, Clinical pharmacology and therapeutics.

[4]  F. Sacks,et al.  Comparison of Excretion of Nicotinuric Acid After Ingestion of Two Controlled Release Nicotinic Acid Preparations in Man , 1988, Journal of clinical pharmacology.

[5]  J. Albers,et al.  Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. , 1985, Metabolism: clinical and experimental.

[6]  M. Cayen.  Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man. , 1985, Pharmacology & therapeutics.

[7]  V. Seiberth,et al.  High-performance liquid-chromatographic determination of free nicotinic acid and its metabolite, nicotinuric acid, in plasma and urine. , 1978, Clinical chemistry.

[8]  H. Bechgaard,et al.  GI absorption of niacin in humans. , 1977, Journal of pharmaceutical sciences.

[9]  W. J. Turner,et al.  Metabolic response of humans to ingestion of nicotinic acid and nicotinamide. , 1976, Clinical chemistry.

[10]  N. Svedmyr,et al.  The relationship between the plasma concentration of free nicotinic acid and some of its pharmacologic effects in man , 1969, Clinical pharmacology and therapeutics.

[11]  L. Carlson,et al.  Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia. , 2009, Acta medica Scandinavica.

[12]  H. L. Mason,et al.  Nicotinic acid treatment of hypercholesteremia. Comparison of plain and sustained-action preparations and report of two cases of jaundice. , 1961, JAMA.